Increased CSF levels of endorphines in chronic psychosis-Reference-Cited by-同舟云学术

Increased CSF levels of endorphines in chronic psychosis

Published:1976-10 Issue:3 Volume:3 Page:157-162
ISSN:0304-3940
Container-title:Neuroscience Letters
language:en
Short-container-title:Neuroscience Letters

Author:

Terenius L.,Wahlström A.,Lindström L.,Widerlöv E.

Publisher

Elsevier BV

Subject

General Neuroscience

Reference16 articles.

1. Clinical observations in manic-depressive disease: a qualitative study of one hundred manic-depressive patients and fifty medically sick controls;Cassidy;J. Amer. Med. Ass.,1957

2. The respiratory, circulatory and narcotic antagonistic effects of nalorphine, levallorphan and naloxone in anesthetized subject;Foldes;Canad. Anaesth. Soc. J.,1969

3. Effect of the opiate antagonist naloxone on body temperature in rats;Goldstein;Life Sci.,1975

4. Gunne, L.-M., Lindström, L.H. and Terenius, L., Naloxone-induced reversal of schizophrenic hallucinations, submitted for publication.

5. Distribution of stereospecific binding of the potent narcotic analgesic etorphine in the human brain: predominance in the limbic system;Hiller;Res. Commun. Chem. Path. Pharmacol.,1973

Cited by 272 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reward processing in schizophrenia and its relation to Mu opioid receptor availability and negative symptoms: A [11C]-carfentanil PET and fMRI study;NeuroImage: Clinical;2023

2. OPIOID PEPTIDES AND RECEPTORS IN RELATION TO AFFECTIVE ILLNESS. EFFECTS OF DESIPRAMINE AND LITHIUM ON OPIOID RECEPTORS IN RAT BRAIN.;Acta Pharmacologica et Toxicologica;2009-03-13

3. Canine Behavior of Sensory and Neural Origin;Canine Behavior;2009

4. Sensorimotor gating and attentional set-shifting are improved by the μ-opioid receptor agonist morphine in healthy human volunteers;The International Journal of Neuropsychopharmacology;2008-01-16

5. Food Intake and Reward Mechanisms in Patients with Schizophrenia: Implications for Metabolic Disturbances and Treatment with Second-Generation Antipsychotic Agents;Neuropsychopharmacology;2006-03-15